The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol
Tóm tắt
Ibuprofen and paracetamol differ in their mode of action and related therapeutic effects, suggesting that combined administration may offer improved analgesia. Reported here are the results of two studies on the pharmacokinetic properties of a novel ibuprofen (200 mg) and paracetamol (500 mg) fixed-dose combination tablet. Both studies were open-label, randomised studies in healthy volunteers: Study 1 was a four-way crossover, single-dose study; Study 2 was a two-way cross-over, repeat-dose study. Pharmacokinetic parameters for ibuprofen and paracetamol were similar for the combination and monotherapy tablets (values falling within the 80% to 125% acceptable bioequivalence range) except for the rate of absorption of paracetamol from the combination (tmax), which was significantly faster compared with monotherapy (median difference 10 minutes; p < 0.05). Mean plasma concentrations of both drugs were higher, earlier, following administration of the combination tablet compared with monotherapy. Mean plasma levels at 10 and 20 minutes were 6.64 μg.mL-1 and 16.81 μg.mL-1, respectively, for ibuprofen from the combination, compared with 0.58 μg.mL-1 and 9.00 μg.mL-1, respectively, for monotherapy. For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 μg.mL-1 and 14.54 μg.mL-1, respectively, for the combination compared with 0.33 μg.mL-1 and 9.19 μg.mL-1, respectively, for monotherapy. The rate of absorption of both ibuprofen and paracetamol was significantly delayed when the combination tablet was administered in the fed versus fasted state; median delay was 25 minutes for ibuprofen (p > 0.05) and 55 minutes for paracetamol (p < 0.001). The pharmacokinetic parameters were comparable irrespective of whether the combination tablet was given twice or three times daily; systemic exposure was, however, approximately 1.4 times greater for both drugs when given three times daily. Administration of ibuprofen and paracetamol in a fixed-dose combination tablet does not significantly alter the pharmacokinetic profiles of either drug, except for enhancing the rate of paracetamol absorption, offering potential therapeutic benefits in relation to the onset of analgesia. Concentrations of both drugs reached previously reported therapeutic levels when the combination tablet was administrated in the fed or fasted state. Three times daily dosing may offer enhanced therapeutic effect for longer than twice daily dosing.
Tài liệu tham khảo
Vane JR, Botting RM: Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl. 1996, 102: 9-21. 10.3109/03009749609097226.
Bonnefont J, Courade JP, Alloui A, Eschalier A: Antinociceptive mechanism of action of paracetamol. Drugs. 2003, 63 (Spec No 2): 1-4. 10.2165/00003495-200363992-00002.
Dollery C: Therapeutic Drugs. 1999, Churchill Livingstone, 2:
Schachtel BP, Fillingim JM, Thoden WR, Lane AC, Baybutt RI: Sore throat pain in the evaluation of mild analgesics. Clin Pharmacol Ther. 1988, 44: 704-711. 10.1038/clpt.1988.215.
Sunshine A, Olson NZ, Laska EM, Zighelboim I, De Castro A, De Sarrazin C: Ibuprofen, zomepirac, aspirin, and placebo in the relief of postepisiotomy pain. Clin Pharmacol Ther. 1983, 34: 254-258. 10.1038/clpt.1983.162.
Wright CE, Antal EJ, Gillespie WR, Albert KS: Ibuprofen and acetaminophen kinetics when taken concurrently. Clin Pharmacol Ther. 1983, 34: 707-710. 10.1038/clpt.1983.237.
CPMP/EWP/QWP/1401/98: Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 2001, [http://www.emea.europa.eu/pdfs/human/qwp/140198enrev1.pdf]
CPMP/EWP/240/95: Note for Guidance on Fixed Combination Medicinial Products. 1996, [http://www.ikev.org/haber/bioav/024095en.pdf]
US department of Health and Human Services FaDCfDEaRC: Guidance for Industry: Bioavailability and Bioequivalence for Orally Administered Drug Products - General Consideration. 2001, [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf]
US department of Health and Human Services FaDCfDEaRC: Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. 2002, [http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf]
Diletti E, Hauschke D, Steinijans VW: Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991, 29: 1-8.
Chen X, Huang J, Kong Z, Zhong D: Sensitive liquid chromatography-tandem mass spectrometry method for the simultaneous determination of paracetamol and guaifenesin in human plasma. Journal of Chromatography B. 2005, 817: 263-269. 10.1016/j.jchromb.2004.12.011.
Prescott LF: Paracetamol (acetaminophen). A Critical Bibliographic Review. 2000, Taylor and Francis Publishers, 289-297.
Davies NM: Clinical pharmacokinetics of ibuprofen The first 30 years. Clin Pharmacokinet. 1998, 34: 101-154. 10.2165/00003088-199834020-00002.
Forrest JA, Clements JA, Prescott LF: Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet. 1982, 7: 93-107. 10.2165/00003088-198207020-00001.
Laska EM, Sunshine A, Marrero I, Olson N, Siegel C, McCormick N: The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther. 1986, 40: 1-7. 10.1038/clpt.1986.129.
Anderson BJ, Holford NH, Woollard GA, Kanagasundaram S, Mahadevan M: Perioperative pharmacodynamics of acetaminophen analgesia in children. Anesthesiology. 1999, 90: 411-421. 10.1097/00000542-199902000-00014.
Brown RD, Kearns GL, Wilson JT: Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children. J Pharmacokinet Biopharm. 1998, 26: 559-579.
Rumack BH: Aspirin versus acetaminophen: a comparative view. Pediatrics. 1978, 62: 943-946.
Seymour RA, Rawlins MD: Pharmacokinetics of parenteral paracetamol and its analgesic effects in post-operative dental pain. Eur J Clin Pharmacol. 1981, 20: 215-218. 10.1007/BF00544600.
Raffa RB: Pharmacology of oral combination analgesics: rational therapy for pain. Journal of Clinical Pharmacology. 2001, 26: 257-64.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6904/10/10/prepub